Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab + Docetaxel + Capecitabine as neoadjuvant therapy in primary breast cancer
2005-005883-10Phase 2Completed
- Sponsor
- Roche
- Start
- Jan 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in breast cancer, sponsored by Roche. Primary endpoint: Pathologic complete response rate. Started Jan 2006; status: completed.
02
Drugs
bevacizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2005-005883-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005883-10.